Zim Laboratories' Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Zim Laboratories Ltd reported a 21.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 12.5%.
- Its expenses for the quarter were up by 14.5% QoQ and 12.9% YoY.
- The net profit decreased 1147.6% QoQ and increased 10.0% YoY.
- The earnings per share (EPS) of Zim Laboratories Ltd stood at 0.9 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 110.36 | 90.75 | 98.08 | 21.6% | 12.5% |
Total Expenses | 104.31 | 91.10 | 92.38 | 14.5% | 12.9% |
Profit Before Tax | 6.05 | -0.34 | 5.70 | -1879.4% | 6.1% |
Tax | 1.65 | 0.08 | 1.70 | 1962.5% | -2.9% |
Profit After Tax | 4.40 | -0.42 | 4.00 | -1147.6% | 10.0% |
Earnings Per Share | 0.90 | -0.09 | 0.82 | -1100.0% | 9.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zim Laboratories Ltd is a company engaged in the pharmaceutical industry, primarily involved in the development, manufacturing, and marketing of pharmaceutical products. The company specializes in innovative drug delivery systems, which enhance the effectiveness and compliance of medications. While specific recent developments of the company are not provided in the current data set, it is known for its focus on research and development within the pharmaceutical sector. Zim Laboratories Ltd operates in a competitive market where technological advancements and regulatory compliance play significant roles.
Revenue
For the third quarter of fiscal year 2026 (Q3FY26), Zim Laboratories Ltd reported a total income of ₹110.36 crores. This represents a significant increase of 21.6% compared to the preceding quarter (Q2FY26), which recorded a total income of ₹90.75 crores. Year-over-year, the total income rose by 12.5% from ₹98.08 crores in Q3FY25. The revenue growth observed both on a QoQ and YoY basis indicates a positive trend in the company's sales performance during this period.
Profitability
The company showed a marked improvement in profitability for Q3FY26 with a Profit Before Tax (PBT) of ₹6.05 crores, compared to a loss of ₹0.34 crores in Q2FY26. This reflects a substantial QoQ change of -1879.4%. On a YoY basis, PBT increased by 6.1% from ₹5.70 crores in Q3FY25. After accounting for taxes amounting to ₹1.65 crores, the Profit After Tax (PAT) for Q3FY26 was ₹4.40 crores, showing a significant recovery from a loss of ₹0.42 crores in the previous quarter. Compared to Q3FY25, the PAT increased by 10.0% from ₹4.00 crores. Earnings per share (EPS) also improved to ₹0.90 in Q3FY26, from a negative value of ₹-0.09 in Q2FY26, and shows a YoY increase of 9.8% from ₹0.82 in Q3FY25.
Operating Metrics
The total expenses for Zim Laboratories Ltd in Q3FY26 amounted to ₹104.31 crores, which represents a 14.5% increase from Q2FY26, where the total expenses were ₹91.10 crores. Year-over-year, expenses rose by 12.9% from ₹92.38 crores in Q3FY25. The tax expense for Q3FY26 was ₹1.65 crores, showing a substantial increase from ₹0.08 crores in Q2FY26, and a slight decrease of 2.9% from ₹1.70 crores in Q3FY25. The financial data reflects significant changes in both revenue and expenses, contributing to the overall financial performance of the company for the quarter.